Welcome to AiCuris: The Powerhouse for Anti-infectives
“Committed to making the difference”
AiCuris is a pharmaceutical company focused on the discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 as a spin-out from Bayer's virology and bacteriology research department, AiCuris is now an established “powerhouse for anti-infectives” and is one of the few biotech companies world-wide to have successfully brought a drug to market, and therefore to patients (Prevymis® 2017/18).
Today AiCuris has an innovative pipeline of anti-infective agents and a team of internationally recognized scientists in Research and Development. By focusing on therapeutic areas with high medical need, the company is positioned for growth and success.
Royalty Pharma - AiCuris
|
| Royalty Pharma Acquires Partial Royalty Interest on Prevymis™ (Letermovir) from AiCuris Anti-infective Cures GmbH |
- Royalty Pharma and AiCuris announced today that they have entered into an agreement whereby Royalty Pharma has acquired a partial royalty interest on Prevymis™[1] (letermovir) from AiCuris for a one-time-payment of $220 million. Prevymis is licensed by MSD, the tradename of Merck & Co. Inc., Kenilworth, N.J., USA.
Breakthrough Therapy Designation
|
| AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients |
- Receiving Breakthrough Therapy Designation will facilitate AiCuris goal of bringing pritelivir to patients as quickly as possible
- AiCuris is currently preparing to add a pivotal Phase 3 trial part to the ongoing Phase 2 study in immunocompromised patients whose HSV infections have become resistant to acyclovir as a basis for NDA submission
- The company to discuss partnering opportunities at upcoming BIO Digital
Corona diagnostic support for NRW
|
| Together with state-run veterinary institutes in NRW AiCuris is involved in carrying out approximately 20,000 tests against SARS-CoV-2 |
- Following the increased incidence of coronavirus infections among employees of a slaughterhouse in Coesfeld, all of the approx. 20,000 employees and contract workers of slaughterhouses in NRW are currently being tested
- AiCuris has been involved at many levels since the outbreak of the pandemic and has established and made available SARS CoV-2 testing capacities at short notice to contribute to the fight against the corona pandemic